GLP-1 and Thyroid Function: What Patients Need to Know About Thyroid Cancer Risk

May 24, 2026

GLP-1 and Thyroid Function: What Patients Need to Know About Thyroid Cancer Risk

By Dr. Onikepe Adegbola, MD PhD — Johns Hopkins-trained physician-scientist and founder of Casa de Sante

Key Takeaways

Every GLP-1 medication carries an FDA boxed warning about medullary thyroid carcinoma (MTC) risk. This is the most prominent warning on these drugs — and also one of the most misunderstood. Here's what the warning means and what it doesn't.
The evidence: in rodent studies, GLP-1 receptor agonists caused dose-dependent increases in C-cell tumors (including MTC) in rats and mice. The doses used were far higher than human therapeutic doses, and the exposure duration was the rodent's entire lifespan.
In humans: to date, epidemiological studies have NOT found an increased rate of MTC in GLP-1 users compared to the general population. A 2023 meta-analysis of clinical trial data found no significant signal.
The boxed warning exists because the rodent data CANNOT be completely dismissed, and MTC is rare enough that even large clinical trials may not detect a small increase. It's precautionary, not confirmatory.

Understanding the Risk

What Is Medullary Thyroid Carcinoma?

MTC arises from C-cells (parafollicular cells) of the thyroid — different from the far more common papillary and follicular thyroid cancers.
MTC accounts for only 3-5% of all thyroid cancers. It's rare: about 1,000 new cases per year in the US.
25% of MTC cases are hereditary (MEN2A or MEN2B syndromes, caused by RET proto-oncogene mutations). 75% are sporadic.
MTC produces calcitonin — a blood test that serves as both a screening and monitoring marker.

The Rodent Studies

Rats and mice express high levels of GLP-1 receptors on thyroid C-cells. GLP-1 receptor activation → C-cell proliferation → C-cell hyperplasia → C-cell tumors (including MTC).
Critical difference: human thyroid C-cells express MUCH lower levels of GLP-1 receptors than rodent C-cells. Some studies suggest human C-cells have minimal or no functional GLP-1 receptor expression.
Human calcitonin studies: patients on semaglutide for 2+ years do NOT show significant calcitonin elevations (which would indicate C-cell stimulation).

Who Should NOT Take GLP-1

Personal history of MTC: Absolute contraindication. Previous MTC → GLP-1 is off-limits.
Family history of MTC: Contraindicated. If a first-degree relative has had MTC, GLP-1 should not be prescribed.
MEN2A or MEN2B syndrome: These genetic conditions predispose to MTC. GLP-1 is contraindicated.
If uncertain: RET proto-oncogene genetic testing can determine if you carry a MEN2 mutation. Consider testing before starting GLP-1 if you have a family history of thyroid cancer (any type).

GLP-1 and General Thyroid Function

Hypothyroidism

GLP-1 does NOT affect thyroid hormone production (T3/T4). Patients with hypothyroidism on levothyroxine can safely take GLP-1.
However: GLP-1's delayed gastric emptying can theoretically affect levothyroxine absorption. Take levothyroxine on an empty stomach, 30-60 minutes before food (standard guidance), and monitor TSH levels after starting GLP-1.
Weight loss itself affects thyroid hormone metabolism: reduced body mass → reduced T3 requirements → TSH may shift. Your endocrinologist may need to adjust levothyroxine dosing during significant weight loss.

Hashimoto's Thyroiditis

GLP-1's anti-inflammatory effects may theoretically benefit autoimmune thyroid conditions (reducing inflammatory cytokines). However, there are no specific studies on GLP-1 in Hashimoto's patients.
Weight loss in Hashimoto's patients can be especially challenging due to metabolic slowdown. GLP-1 provides a pharmacological assist that dietary approaches alone often can't achieve in this population.

Monitoring Recommendations

Before starting GLP-1: baseline thyroid exam (physical) and review of family history for MTC.
During treatment: no routine calcitonin screening is recommended for the general population (false positives are common and cause unnecessary anxiety and procedures).
Report symptoms: new neck lump, persistent hoarseness, difficulty swallowing, or neck pain → evaluate for thyroid pathology.

🛒 Thyroid + GLP-1 Support

Daily Vitamin — Selenium is essential for thyroid hormone conversion (T4 → active T3). Iodine is the building block of thyroid hormones. Zinc supports thyroid hormone synthesis. For patients managing both thyroid disease and GLP-1 weight loss, these micronutrients are critical — and all three can be depleted during reduced food intake.
Digestive Enzymes — If GLP-1's delayed gastric emptying is affecting your levothyroxine absorption (which you'd see as rising TSH despite consistent dosing), enzymes help ensure complete food digestion and may improve the predictability of medication absorption by reducing gastric transit variability.

Medical Disclaimer: This article is for educational purposes only. The thyroid boxed warning on GLP-1 medications is an active area of research. Discuss your personal and family thyroid cancer history with your prescriber before starting GLP-1. If you develop a thyroid nodule or neck lump while on GLP-1, get it evaluated promptly. Dr. Adegbola is the founder of Casa de Sante.

Back to blog

Keto. Paleo. No Digestive Triggers. Shop Now

No onion, no garlic – no pain. No gluten, no lactose – no bloat. Low FODMAP certified.

Stop worrying about what you can't eat and start enjoying what you can. No bloat, no pain, no problem.

Our gut friendly keto, paleo and low FODMAP certified products are gluten-free, lactose-free, soy free, no additives, preservatives or fillers and all natural for clean nutrition. Try them today and feel the difference!